BNF 83 (British National Formulary) March 2022

Product Information

Vaccines update: restructure of monograph content—creation of two class monographs, Vaccines, general (information common to all vaccines) and Vaccines, live (information relevant to live vaccines only); see examples in yellow fever vaccine or hepatitis A vaccine. Drugs that cause first dose hypotension, drugs that cause peripheral neuropathy, and drugs that cause hyponatraemia: pharmacodynamic effects drug groups revalidated and updated; see Appendix 1 interactions. The British National Formulary is published jointly by BMJ and Pharmaceutical Press, the publishing division of Royal Pharmaceutical Society. The BNF for Children is published jointly by BMJ, Pharmaceutical Press, the Royal College of Paediatrics and Child Health and the Neonatal and Paediatric Pharmacy Group. Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia [MHRA/CHM advice] (advice in calcium gluconate). To read this ebook on a mobile device (phone or tablet) you'll need to install one of these free apps:

BNF 83 (British National Formulary) March 2022 83rd Revised

This update contains 3 significant changes, 1 dose change, 3 new monographs, and 3 deleted monographs. The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. The new edition (BNF 83) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines. Table of Contents: Hyoscine hydrobromide patches ( Scopoderm® 1.5 mg patch or Scopoderm® TTS patch): risk of anticholinergic side effects, including hyperthermia [MHRA/CHM advice].Selective serotonin re-uptake inhibitors: breast-feeding advice for all drugs in class and individual drug monographs updated (see examples in fluoxetine and sertraline). Rabies vaccine [update to pre-exposure immunisation booster dose in patients who may have frequent, unrecognised exposures e.g. bat handlers]. Adrenaline/epinephrine: recall of Emerade® 500 micrograms and Emerade® 300 micrograms auto-injectors, due to the potential for device failure [National Patient Safety Alert advice]. The BNF is jointly published by the Royal Pharmaceutical Society and BMJ. BNF is published in print twice a year and interim updates are issued and published monthly in the digital versions. The following summary provides a brief description of some recent key changes that have been made to BNF content. Direct-acting oral anticoagulants (DOACs): reminder of dose adjustments in patients with renal impairment [MHRA/CHM advice] (advice in apixaban, dabigatran etexilate, edoxaban, and rivaroxaban; see example in dabigatran etexilate).

BNF Publications Online Access British National Formulary | BNF Publications

Specialist drug” monographs within BNF Publications: identification and reduced level of detail, see How to use BNF Publications online. Mental Health and Criminal Justice Bridging the Gap by J. Steven Lamberti,Robert L. Weisman,Vivek Furtado This edition of BNF continues to broadly follow the high-level structure of previous editions of BNF. Preliminary material, including information on how to use the BNF, significant changes to the content in each edition, and guidance on various prescribing issues (eg, prescription writing, use of intravenous medications, particular considerations for special patient populations). Chapters, which contain drug monographs that describe the uses, dosages, safety issues, and other considerations involved in drug use; drug class monographs; and treatment summaries, which include guidance on medication selection. Treatment monographs and summaries are divided into chapters based on specific aspects of medical care, such as Chapter 5, Infections, or Chapter 16, Emergency Treatment of Poisoning; or drug use related to a particular body system, such as Chapter 2, Cardiovascular. Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality [MHRA/CHM advice] (advice in abrocitinib, baricitinib, filgotinib, tofacitinib, upadacitinib; see example in tofacitinib).If you’re a UK-based individual undertaking work or training for the NHS, you can register for access to BNF content on MedicinesComplete. As a registered NHS user, you’ll get single user access to BNF and BNF for Children content on MedicinesComplete for 365 days.

BNF 83 (British National Formulary) March 2022 PDF Free BNF 83 (British National Formulary) March 2022 PDF Free

This update contains 12 significant changes, 4 dose changes, 1 classification change, 5 new monographs, 1 new preparation, 1 deleted monograph and 1 deleted preparation. This update contains 5 significant changes, 2 new monographs, 2 new preparations, 4 deleted monographs and 2 deleted preparations. Drugs that cause thromboembolism: pharmacodynamic effects drug group deleted from Appendix 1 interactions.The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care. Drugs that cause hepatotoxicity, drugs with CNS depressant effects, and drugs that increase serum potassium: pharmacodynamic effects drug groups revalidated and updated; see Appendix 1 interactions.

BNF83 (British National Formulary)

Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease [MHRA/CHM advice]. This update contains 14 significant changes, 5 dose changes, 1 new monograph, 4 new preparations, 2 deleted monographs and 1 deleted preparation. Azithromycin [update to dosing for uncomplicated non-gonococcal urethritis in children aged 12 to 17 years old]. Controlled drugs and drug dependence: updated guidance on prescription requirements for Schedule 2 and 3 Controlled Drugs.

Non-steroidal anti-inflammatory drugs: potential risks following prolonged use after 20 weeks of pregnancy [MHRA/CHM advice].